Exact Sciences Corp.
Company Snapshot
Founded: 1995
Entity Type: Public
Employees: 7,000
Region: U.S.
Revenue: $2,758.9 Millions
Revenue Year: 2024
Headquarter: Wisconsin, U.S.
Key Geographics: U.S., Outside of U.S.
Corporate Address: 5505 Endeavor Lane Madison, Wisconsin 53719 U.S. 1-608-284-5700 www.exactsciences.com
Company Overview
Exact Sciences Corp. is an advanced cancer diagnostics company. Its revenues are primarily generated by its laboratory testing services from its Cologuard colorectal cancer screening and Oncotype DX cancer diagnostic tests and services. Building on the success of Cologuard and Oncotype tests, the company is expanding its product range to target some of the most challenging cancers and improve patient outcomes.
Financial Highlights (FY 2024)
Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***
This information is available for BCC Research members only.
Exact Sciences Corp. In News
Company's Business Segments
- Screening : This segment includes the Cologuard test, a noninvasive, stool-based DNA (cDNA) screening test, and Clinical Genetic testing, which provides more than 5,000 predefined genetic tests for all genes, additional custom panels, and comprehensive germline, whole exome (PGxome ), and whole genome (PGnome) sequencing tests.
- Precision Oncology : This portfolio provides better genomic insights to inform prognosis and cancer treatment after a diagnosis. This test includes the Oncotype DX Breast Recurrence Score, Oncotype DX Breast DCIS Score, and OncoExTra tests.
Applications/End User Industries
- Healthcare Industry
- Genomics
- Oncology
- Clinical Testing
BCC Research Beacon 